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The impacts of diabetes research from 31 European countries in 
2002 to 2013 
Abstract 
The evaluation of a country’s medical research outputs should include measures of their impact 
on medical practice, on health policy and decision-making, as well as conventional citations in 
the serial literature. This study examined three measures of impact: geometric mean, arithmetic 
mean and world scale mean, applied to one disease area, namely diabetes, to investigate the 
amount of agreement between them in terms of the impacts of the research of different European 
countries. Firstly, citations to diabetes research papers in the Web of Science from 31 European 
countries from 2002 to 2013 were analysed. Papers from Finland, Switzerland, Denmark and the 
UK were the most cited by other papers on both geometric and arithmetic means, and in terms of 
their presence in the top 5% of papers with the most citations. Secondly, the references on 103 
European diabetes clinical practice guidelines from 21 countries were analysed. Papers from the 
Netherlands, Finland, the UK and Austria were the most cited in the clinical guidelines relative to 
the countries’ presence amongst diabetes research. Finally, an analysis of newspaper stories about 
non-communicable disease research from 22 European countries included 822 on diabetes 
research (9.6% of the total) and showed that the subject was of substantial interest. The countries 
whose papers were the most cited relative to their presence in the subject area were Finland, 
Norway, the UK and Belgium; those from Japan, China and South Korea were not well cited. 
Different European countries scored highly on these three measures. Scandinavian countries and 
the UK appeared to perform strongly on all three, but Switzerland only on conventional citation 
counts. The increased emphasis placed on demonstration of the social and economic impacts 
stemming from research make the described methodologies herein of particular value to future 
evaluations of medical research. 
Keywords: diabetes, citations, clinical practice guidelines, newspaper stories, research impact, 
research evaluation 
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Introduction 
The evaluation of research can be performed at the individual level (e.g. as a guide to promotion 
or to the award of research grants (Lewison, Cottrell, and Dixon 1999)), institutional level (where 
universities vie to ascend the rankings in various league tables (Fowler 2014)), or national level 
(where it can show if a country’s research policies are effective (Ding et al. 2013; Campbell et al. 
2010)). It is, or should be, concerned both with scientific excellence and the practical 
implications of the research in the real world. The balance between these two criteria depends 
very much on the subject matter, but most medical research needs to be judged on both. 
There is an extensive literature on the way to measure research excellence, and this is 
conventionally based on a combination of peer review and citation counts of papers by other 
research papers (Hirsch 2005; Moed 2007; Neylon and Wu 2009; Insights 2013). To some extent 
these are related, because papers submitted to journals are subjected to peer review and the higher 
the prestige of the journal, the stricter the peer review (and the higher the rejection rate). This in 
turn tends to help papers in leading journals to gather citations from other authors, and although 
many papers achieve citation scores well above or below the average for their journal, by 
definition, the average of their scores will reflect the journal impact factors calculated on a 
diachronous basis. 
The difficulty is that citation counts are not normally distributed, and so their arithmetic mean is 
not regarded as a valid indicator of the impact of one group of papers compared with another 
(Bornmann et al. 2008; Weale, Bailey, and Lear 2004; Gargouri et al. 2010; Nieminen et al. 
2006). It has recently been suggested that their geometric mean is a better measure (Bornmann et 
al. 2008; Weale, Bailey, and Lear 2004; Gargouri et al. 2010; Nieminen et al. 2006), although 
this has to be calculated by the addition of unity to each score, and then deducted from the 
(enhanced) mean value. 
Alternatively, the numbers of papers from a group that receive enough citations to put them in the 
top centiles of the field have been viewed as a better criterion as some authors consider that only 
these papers are really important (Waltman and Schreiber 2013). The method of calculation of 
the appropriate indicators was discussed by Bornmann (2013). However, several authors have 
examined the papers in the top centiles of their field without taking account of the time window 
for citations (for example, Aminian et al, 2014; Li & Jiang, 2016; Kim et al., 2017). This clearly 
will disadvantage countries (and institutions) whose output has expanded rapidly as their papers 
will have had less time to garner citations. It is essential to use a fixed citation window for this 
and other analyses of citation counts. 
All three indicators have merit, so that if a country or institution scores highly on all three, its 
research can be considered as meritorious. However, there is an important caveat: all the citation 
scores should be based on fractional counts of how much a country contributed to a paper, not 
integer counts of the number of papers they contributed to, as otherwise small countries, most of 
whose output is multi-national, will benefit disproportionately from the high citation counts that 
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such papers often attract (Rodríguez-Navarro 2012; Waltman and van Eck 2015). For example, in 
our study we found that Danish diabetes papers had a mean five-year citation count in the Web of 
Science (WoS, © Clarivate Analytics) of 27.8 cites on an integer count basis, but only 20.6 cites 
on a fractional count basis. Consequently, all the citation count data presented in this paper are 
based on fractional address counts. 
Research influence can also be assessed by the extent to which a paper is cited internationally. 
Research papers tend to be more frequently cited by their authors’ fellow citizens than would be 
expected from their countries’ presence in the literature of the given subject (Smith et al. 2014). 
The “Over-Citation Ratio” (OCR) is greater for countries with a small output of research papers 
but it is decreasing with time as communication becomes easier.  
However, it is arguable that indicators based on the “real world” provide a better measure of 
research merit or utility. In this study, in addition to traditional research impact metrics, we 
investigated from an international perspective the references on clinical practice guidelines 
(CPGs), and the papers written about in newspaper stories of progress and advances in 
biomedical science related to a specific condition, here, diabetes. There is already evidence that 
papers informing medical practice also achieve high citation scores (Thelwall & Maflahi, 2016; 
Thelwall et al., 2017). 
CPGs are increasingly being produced by national government agencies, regional governments 
(e.g., in Scotland, the provinces of Spain and counties of Sweden), and international specialist 
societies. In diabetes, the number of produced clinical guidelines in Europe rose from hardly any 
at the beginning of this century to about 15 per year recently. They are increasingly being used to 
guide clinical practice (Payne et al. 2013; Corwin et al. 2014), but with variable actual impact 
(Polk et al. 2016). There have been a number of studies (Grant et al. 2000; Kryl et al. 2012) on 
the references that they cite as evidence, but all have covered just one country except for that of 
Andersen (2013). However, because the papers cited by CPGs are relatively clinical, rather than 
basic, these citations can only be used for the evaluation of clinical work. They do, however, 
redress the balance somewhat because basic research tends to be better cited than clinical work in 
the academic literature (Gee & Narin, 1986; Lewison & Devey, 1999; van Eck et al., 2013). 
Medical research affects the public more than research in almost all other fields, and in Western 
Europe, it receives significant support from the non-profit sector, particularly charities (Dawson 
et al. 1998). Citizens are expected actively to take some care of their own health, and when they 
become ill, are encouraged to act as educated consumers rather than as passive patients. They can 
obtain information from a variety of sources, including newspapers, whose stories (unlike those 
on social media websites) are relatively permanent and can be analysed by bibliometricians. 
Despite declining circulations, newspapers can still be very influential with politicians, their 
advisers, healthcare professionals, researchers and the general public. Indeed, stories in 
newspapers (Phillips et al. 1991) and from broadcasters (Lewison and Sullivan 2008) have been 
shown to lead to more citations in the literature. There have been many studies of mass media 
reports of medical research (Hanson et al. 2017; Lai and Lane 2009; Akamatsu, Naito, and 
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Nakayama 2009; Bartlett, Sterne, and Egger 2002); very few have been able to cover newspapers 
in multiple countries (Lewison 2008; Pallari et al. 2017; Casino et al. 2017).  
Both these indicators involve work with many different European languages, which was made 
possible within the EU-funded project (MAPPING NCD) on the mapping of research outputs 
across five chronic non-communicable diseases and their impact. In this paper, the focus is on 
countries as units of assessment, rather than research institutions. This way the different entities 
should have enough published papers for comparisons to be made on the basis of both clinical 
guideline and newspaper citations, which are inevitably far fewer than those in the serial 
academic literature. However, we have also considered the citations to different subject areas 
within diabetes research because these can affect the apparent performance of individual 
countries, which may concentrate their research efforts on different areas. For example, Italy 
carried out relatively more research on the effects of diabetes on the liver than Germany, but the 
reverse was true for research on the effects on feet (Begum et al., 2017; Table 1). As we shall see, 
research on the effects on the liver is much better cited than research on the effects on feet (Table 
4), and this is part of the reason why Italy’s citation performance overall is superior to that of 
Germany (Table 3). 
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Methodology 
Sample 
With the help of our European partners and King’s College London graduate students with 
relevant language skills, we collected outputs of diabetes research in the WoS from 31 European 
countries (EUR31): the 28 Member States of the European Union plus Iceland, Norway and 
Switzerland. A list of these countries, and some others, with their ISO2 codes is given in Table 1. 
In addition, we searched many European newspapers for stories about non-communicable disease 
research, including diabetes, and compiled a database of their parameters, and of the WoS papers 
that they cited. Finally, we compared the OCR for references on CPGs and for papers cited in 
newspaper stories, with those found for journal papers, to see if these two types of documents 
were more or less nationalistic in their choice of research literature. 
Table 1. List of countries with their International Standards Organization digraph (ISO2) codes. 
ISO2 Country   ISO2 Country   ISO2 Country 
AT Austria   FR France   NL Netherlands 
AU Australia   GR Greece   NO Norway 
BE Belgium   HR Croatia   PL Poland 
BG Bulgaria   HU Hungary   PT Portugal 
BR Brazil   IE Ireland   RO Romania 
CA Canada   IL Israel   SE Sweden 
CH Switzerland   IN India   SG Singapore 
CN China (P.R.)   IS Iceland   SI Slovenia 
CY Cyprus   IT Italy   SK Slovakia 
CZ Czech Rep.   JP Japan   TR Turkey 
DE Germany   KR Korea (South)   TW Taiwan 
DK Denmark   LT Lithuania   UK United Kingdom 
EE Estonia   LU Luxembourg   US United States 
ES Spain   LV Latvia     
FI Finland  MT Malta    
The database of diabetes papers was created by means of a special “filter” that was applied to the 
WoS, both the Science Citation Index-Expanded and the Social Sciences Citation Index, for 
2002-13. This filter contained the names of 45 specialist journals (which accounted for 42% of 
the diabetes papers) and 35 selected title words and was developed in consultation with Diabetes 
UK and Bocconi University. It had a precision (p, specificity) of 0.90 and a recall (r, sensitivity) 
of 0.98, and a calibration factor of p/r=0.92. It identified 40,547 papers (articles and reviews) in 
the WoS for the 12-year period, which were downloaded as text files, and then converted to a MS 
Excel spreadsheet by means of a special VBA program written by Philip Roe of Evaluametrics 
Ltd. 
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Citations of papers in the serial literature 
The diabetes papers from the years 2002-11 were divided up into several groups, each of fewer 
than 10,000 (which is the upper limit permitted for citation scores to be determined with the 
WoS), so that a citation analysis could be carried out. The WoS allows citation data to be 
downloaded, 500 papers at a time, as a series of Excel files, which can then be combined into a 
single file by means of another VBA program. This included the original paper titles and sources 
in exactly the same formats as those in the original file of papers. Citation counts were 
determined for the first five years, including the publication year; this is a compromise between 
the need for immediacy and enough time for the peak citation year to be included. This is referred 
to as Actual Citation Impact (ACI). The ACI values were transferred to the file of papers by 
means of a match on the paper titles. This was not possible for some papers, either because the 
title was too long (> 255 characters), or because it contained special characters like quotation 
marks or semi-colons. For these papers, a match was made on the source (journal, year, volume, 
issue, pages), or on part of the title not containing special characters, and the ACI values were 
then copied across. Although the WoS may contain more than one document with the same title, 
the others are usually correspondence following publication of the original paper, and these are 
not articles or reviews. 
The papers’ addresses were parsed to show the fractional counts of each European country’s 
contribution, and these fractional counts were multiplied by the ACI value of each of the papers 
to give a fractional count of citations for each country. In addition, each ACI value was increased 
by unity, and then its logarithm to base 10 was calculated. These converted citation scores for 
each paper were also multiplied by each country’s fractional contribution. The sums of the 
original and of the converted weighted citation counts for each EUR31 country were calculated, 
and then divided by the total fractional counts of the number of citable papers to give two mean 
values. Those of the converted citation counts were then used as the exponents of 10, and unity 
subtracted from the results, to give the geometric mean citation count, as compared with the 
arithmetic mean. (Typically, the geometric mean calculated in this way is about half as large as 
the arithmetic mean, see Tables 3 and 4.) Citation scores were only determined for the EUR31 
countries, and not for the non-EU countries that may have co-authored the papers, as their outputs 
would have been incomplete in our file. 
The percentages of a country’s citable papers that received enough citations to put them in the top 
centiles of the group were easily determined on the basis of fractional counts after the file of 
papers was sorted by ACI score, descending. The over-citation ratio, OCR, was determined for 
the diabetes papers from the leading countries (with at least 1% of world output) in 2005 and 
2010. For example, French diabetes papers in 2005, numbering 318 out of a world total of 6,733, 
or 4.8%, received 906 out of their 6,050 citations in 2005-09 from papers with a French author, 
or 15.0%. So, their OCR was 15/4.8=3.1. A plot of OCR against percentage presence for the 
leading countries showed that it could be represented by means of a power law, and this equation 
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gave OCR values that could be compared with those observed for citations from the CPGs and 
newspaper stories. 
Impacts on clinical practice guidelines and newspaper stories 
We found 103 diabetes CPGs from 21 European countries. The sets of references were tabulated 
into Excel spreadsheets, and then converted into WoS search statements so that the cited papers 
could be identified, and their details downloaded. For some CPGs, it was possible to semi-
automate this process by means of a macro (written by Philip Roe of Evaluametrics Ltd) which 
identified the different components of a reference by the presence of full stops after the list of 
authors and the title, and the year as a number between 1960 and 2015. It then generated search 
statements that contained the three longest words of the title, the publication year and the name of 
up to three authors. However, some references were not journal papers, or were in journals not 
covered by the WoS, and very few were even incorrect. 
We examined what types of diabetes research were involved in the papers cited by the guidelines, 
using the same sub-filters as had been developed for analysis of the European diabetes research 
papers. We also determined which countries’ research had been most cited by the CPGs from 
other countries, compared with their presence in diabetes research as recorded in the WoS. This 
correction was made in order to compensate for bias because some countries published more 
CPGs, and their references, than others. 
The recording of European newspaper stories on biomedical research involved the development 
of a series of protocols, the involvement of a multi-lingual team who underwent training in a 
series of sessions held by EP at KCL and were closely monitored to ensure that all were working 
with the same methodology (Pallari & Lewison, 2017). Diabetes-related search terms were 
developed in English, and then translated into 16 other languages and used to search the archives 
of the selected European newspapers. The English diabetes-related search terms were:  
diabet* + (research* OR study OR scientists OR expert*). 
However, these generated many false positives, and each story identified by these search terms 
had to be read and retained for inclusion only if it was relevant, i.e., it cited an identifiable journal 
paper. The members of the multi-lingual team then extracted salient data from each story into a 
standardised Excel spreadsheet, including translations into English of the headline and a short 
synopsis. The data included codes to connote the NCD and subject areas within it, details of the 
cited paper and also of any commentators on the significance of the results. The researchers then 
searched the WoS for the cited papers, one at a time, and downloaded their bibliographic data to 
numbered files so that they could be matched to the newspaper stories in the main spreadsheet. 
Finally, all the individual contributions were put together to create one multi-national file of both 
stories and cited papers that could be analysed. 
The stories were coded by the researchers to show which research domain was being described, 
and also what type of diabetes or its sequelae, see Table 2. The cited papers were analysed by a 
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VBA program to reveal their research level (from RL=1.0 for clinical observation to RL=4.0 for 
basic research, (Lewison and Paraje 2004)) based on their individual titles and the journals in 
which they were published. They were also analysed by another VBA program to show the 
fractional presence of each country among their addresses. All these parameters could then be 
compared with the corpus of European diabetes research papers in 2002-13 (Begum et al. 2017) 
to show whether the journalists had made an unbiased selection from them, and in particular 
whether they had over- or under-cited the research from their compatriots. Although the papers 
cited by CPGs went back many years before the start date of 2002 for our study, this was much 
less the case for newspaper stories as they tended to report new research results, and only seven 
of the 822 cited papers appeared before 2002. 
Table 2. List of diabetes research subject areas, with codes used for the tables and figures. 
Code Subject area  Code Complications 
TY1 Type 1 diabetes  FEE Feet 
TY2 Type 2 diabetes  CAR Cardiovascular 
GES Gestational diabetes  KID Nephropathy 
NEO Neonatal diabetes  NEU Neuropathy 
MOD Maturity Onset Diabetes of the Young (MODY)  LIV Liver 
ADA Latent Autoimmune Diabetes of Adults (LADA)  HYP Hypoglycaemia 
GEN Genetics  PSY Psychosocial 
   RET Retinopathy 
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Results 
Citations to diabetes research papers 
European diabetes research papers are somewhat more highly cited than the world average 
(arithmetical basis) since 2004, mainly because the latter is increasingly affected by Chinese 
papers, and others from East Asia, which tend not to be well cited. In 2009, for example, the 
mean five-year counts were 17.9 cites for the EUR31 papers, 15.9 cites for the world but only 
14.7 cites for non-European papers. Table 3 shows the citation performance of all 31 European 
countries in 2002-11.  
Table 3. Citation performance of EUR31 in diabetes research in 2002-11, fractional counts, ranked 
by % with 58 or more cites (WorldScale, W.S.), and with five-year citation scores based on 
arithmetic and geometric means. Values of the worldscale, arithmetic (Arith) and geometric (Geom) 
means > twice the European means shaded deep green; if > 1.41 x means shaded light green; if < 0.71 
x means, shaded yellow; if < 0.5 x means, shaded pink. For country codes, see Table 1. 
Country Citable Arith Geom W.S.   Country Citable Arith Geom W.S. 
FI 984 21.6 11.5 145   ES 1798 12.3 6.4 48 
CH 641 19.7 10.0 139   CZ 262 10.1 5.4 45 
BE 590 19.9 9.1 117   LV 17 11.3 5.7 42 
IS 29 35.2 9.1 115   HU 248 10.5 5.5 36 
UK 5376 19.7 9.8 111   EE 30 11.4 7.2 34 
DK 1611 20.6 10.7 110   PT 171 12.4 7.3 32 
NL 1718 18.2 10.6 101   RO 120 6.8 2.8 17 
FR 2517 15.4 6.8 93   LU 7 11.6 6.4 16 
AT 567 14.3 6.7 90   BG 55 6.8 3.2 15 
IT 3328 16.2 8.8 83   GR 616 10.8 6.5 15 
SE 1778 17.7 9.9 78   PL 760 7.6 4.3 14 
DE 4125 13.2 5.8 71   LT 23 5.5 2.0 13 
CY 4 6.9 4.1 71   SK 154 7.1 4.0 9 
NO 371 16.2 9.9 62   HR 134 5.6 3.1 4 
IE 203 13.8 7.0 58   MT 15 3.8 2.5 0 
SI 89 7.9 3.8 55             
The three citation measures are fairly well correlated (r2=0.7), but the rankings are not quite the 
same. Finland (FI) leads in the number of papers in the top 5% and in the geometric mean of all 
its papers, although Iceland (IS), with fewer than 30 papers, has a much higher arithmetic mean. 
It is noticeable that the 13 new “accession Member States” in eastern and southern Europe all 
score less than 0.71 times the mean on either one or both averages, and six of them less than half 
the mean on both averages. 
We found that, of the 31,906 citable papers (see Table 4), the top 5% (1,595 papers) each 
received 58 cites or more; in fact, there were 1,642 papers with this ACI value or greater, that is 
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5.15%. For example, there were 66 such papers with an Austrian address, with a fractional count 
of 26.4 papers. This represented 4.66% of the total (567.0) Austrian fractional count of citable 
papers, so on this criterion Austria scored slightly less than par, or 100x4.66/5.15=90.4 on the 
“WorldScale” system (Lewison et al. 2007), where the mean performance is given a score of 100. 
The 15 subject areas provided on Table 4 also score differently on citation counts.  
Table 4. Citation scores for 15 subject areas in European diabetes research in 2002-11, integer 
counts, ranked by percentage with 58 or more cites (top 5%), and with five-year citation scores 
based on arithmetic and geometric means. Subject percentages in top 5% and values of the arithmetic 
(Arith) and geometric (Geom) means > 1.41 times the European mean shaded green; if < 0.71 x means, 
shaded yellow; if < 0.5 x means, shaded pink. For codes for subject areas see Table 2. 
  Citable 5% WS Arith Geom   Citable 5% WS Arith Geom 
LIV 866 78 175 22.9 13.1 TY1 4603 172 73 14.9 7.8 
TY2 10390 801 150 23.1 11.2 NEU 802 28 68 14.3 8.3 
NEO 183 14 149 21.4 11.4 HYP 91 3 64 11.4 5.8 
GEN 4076 236 112 20.5 10.5 RET 1081 24 43 12.4 6.6 
CAR 4046 226 108 19.0 9.2 MOD 144 3 40 16.3 10.9 
Total 31906 1642 100 17.6 8.5 GES 617 12 38 11.3 6.0 
KID 1950 89 89 16.2 8.1 FEE 672 10 29 11.0 6.3 
PSY 371 14 73 14.1 7.8 ADA 66 0 0 10.3 6.8 
There is less variation between subject areas than between countries, but research papers on the 
effects of diabetes on the liver, type 2 and neonatal diabetes are clearly the most cited, and those 
on latent autoimmune diabetes of adults, the effects on feet and gestational diabetes are the least 
cited. This should be borne in mind if efforts are made within a country to re-balance its diabetes 
research portfolio. 
International citations to European diabetes research papers 
We obtained OCR values for the 22 leading countries in diabetes research in 2005 and 2010. 
However, those whose presence was < 1% of the total were not analysed. This left 17 countries 
for both years of which 11 were European. Figure 1 shows the OCR values in 2010 for these 
countries plotted against their percentage presence in world diabetes research in that year, on log-
log scales. 
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Figure 1. Plot of 17 countries’ Over-Citation Ratio for diabetes research papers against their 
presence in diabetes research in 2010, integer counts. For country codes, see Table 1. 
This figure suggests that most of the countries whose points appear below the line and are over-
citing their own research less than the amount expected are European, but that there are big 
differences between them. Table 5 shows the expected and observed OCRs for the 17 countries 
for which we have reliable data. 
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Table 5. Citations to diabetes research papers in 2010 from 17 countries with > 1% of world (wld) 
outputs, integer counts, over-citation ratio (OCR) observed and expected based on least-squares 
correlation line OCR=10.34*p-0.651, ranked by ratio of observed (obs) to expected (exp) OCR. See 
Table 1 for country ISO codes. 
ISO Papers % wld Cites Own Own, % OCR, obs OCR, exp OCR ratio 
FR 418 4.2 8700 1055 12.1 2.90 4.08 0.71 
DK 307 3.1 7573 830 11.0 3.57 4.98 0.72 
CH 158 1.6 4100 379 9.2 5.85 7.68 0.76 
NL 312 3.1 8505 1068 12.6 4.03 4.93 0.82 
SE 278 2.8 7026 870 12.4 4.46 5.32 0.84 
DE 657 6.6 11226 1908 17.0 2.59 3.04 0.85 
IT 477 4.8 11473 1747 15.2 3.19 3.74 0.85 
ES 308 3.1 6111 840 13.7 4.46 4.97 0.90 
UK 908 9.1 18540 3722 20.1 2.21 2.46 0.90 
AU 419 4.2 9768 1546 15.8 3.78 4.07 0.93 
PL 153 1.5 1745 208 11.9 7.79 7.84 0.99 
BE 118 1.2 2844 330 11.6 9.84 9.29 1.06 
JP 698 7.0 9205 2168 23.6 3.38 2.92 1.16 
BR 332 3.3 3790 703 18.5 5.59 4.74 1.18 
IN 396 4.0 4212 896 21.3 5.37 4.22 1.27 
US 3268 32.7 51299 23284 45.4 1.39 1.07 1.30 
CN 676 6.8 8853 3112 35.2 5.20 2.98 1.74 
According to this criterion, the papers with the least country OCR, compared with that expected 
from their presence in world diabetes research in 2010, were those from France (FR), Denmark 
(DK), Switzerland (CH) and the Netherlands (NL). 
Diabetes clinical practice guidelines and their evidence-base 
There has been a big increase in the number of CPGs on diabetes in the last few years. The 103 
CPGs that we analysed had a total evidence base of 5,941 references, of which the earliest was 
from 1961 and the latest from 2014. Figure 2 shows the percentages of European diabetes 
research papers (abscissa), and the corresponding percentage of these references in each subject 
area on CPGs (ordinate). The relationship is not linear, but the correlation is high, indicating that 
the European diabetes research outputs appear to be appropriate to the evidence cited by CPGs, 
except that this has few papers on genetics (GEN), or liver sequelae (LIV). On the other hand, the 
CPG references included more than 7% on diabetic feet (FEE), whereas these accounted for 
barely 2% of European diabetes research. 
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Figure 2. Relationship between European diabetes research subjects and evidence base of 103 
European clinical practice guidelines. See Table 2 for subject codes. Dashed lines show values twice 
and half those of equivalence. 
The countries whose research is cited by these CPGs are for the most part European ones, see 
Figure 3. The countries whose research is most cited are the Netherlands (NL), Finland (FI) and 
the UK, followed by Austria (AT), Denmark (DK), Switzerland (CH) and Belgium (BE). These 
countries are all publishing papers that are well-cited academically, but not in the same ranking 
order. French research is slightly under-cited by CPGs despite having a fair citation performance 
in Table 3. 
However, these ratios of observed to expected numbers of references are inevitably biased 
because of the varying numbers of references from CPGs from different countries. A fairer basis 
for comparison is to distinguish between references to a country’s papers from its own CPGs, and 
those from CPGs from other European countries. This is shown in Figure 4 for those eight 
European countries with at least 100 references from the 103 diabetes CPGs. 
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Figure 3. Over- (or under-) citation ratio for countries’ papers on European diabetes CPGs 
compared with their presence in diabetes research, 2002-13, integer counts. European countries 
blue, north American countries red, east Asian countries yellow; south American country green, 
Australia orange. See Table 1 for country ISO codes. 
 
Figure 4. Over-citation ratio for eight European countries’ papers cited by diabetes CPGs by own 
country (blue striped columns) and from CPGs from other European countries (red columns) 
compared with their presence in diabetes research, 2002-13, fractional counts. See Table 1 for 
country ISO codes. 
The references on CPGs were very clinical, as expected (Lewison and Devey 1999; Rajendram, 
Lewison, and Preedy 2006; Lewison and Sullivan 2008), and the papers were more clinical than 
the average for the journals in which they were published. On a scale from 1.0=clinical 
observation to 4.0=basic research, the titles of individual guideline reference papers gave an RL 
(papers) of 1.09 compared with 1.68 for EUR31 diabetes research; the corresponding figures for 
the research levels of the journals were 1.44 compared with 1.91. By way of illustration, the 
journals whose research levels in recent years correspond to these values are: 1.09 - BMJ; 1.44 - 
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Diabetes Research & Clinical Practice; 1.68 - Nephrology Dialysis Transplantation; 1.91 - 
Journal of Hypertension. 
Although the earliest paper cited by these CPGs dated from 1961, most were fairly recent, with 
the median year being 2005 and the inter-quartile range being from 2000 to 2008. Figure 5 shows 
that the peak gap between publication of a paper and its citation on a CPG is about two years, and 
just over half the cited references are five years old or more recent. This can be compared with 
the corresponding curves for the temporal distributions of citations to European diabetes papers 
published in 1985 (diachronous citations) and of references on 2013 papers (synchronous 
references). The two synchronous distributions are rather similar, with peaks in the second year 
before publication, but the CPG references are slightly more recent than the WoS ones. This 
shows that the process whereby recent research is taken into account in the development of 
recommendations for clinical practice is good. However, it is not up-to-date in all countries. 
 
Figure 5. The gap between publication of a paper and its citation on a diabetes CPG (red), the gap 
between European diabetes publications in the WoS in 1985 and the years in which they were cited 
diachronously by other papers (green), and the years of the references on European diabetes 
publications in the WoS in 2013 (synchronous, blue). 
There were rather large differences between countries in the immediacy of the evidence that was 
cited by their diabetes CPGs, as shown in Figure 6. The range was from 10 years for Finland (FI) 
to only three years for Croatia (HR). This last finding is perhaps surprising, as Croatia is not 
particularly research-active in diabetes, and none of the 81 references on its two CPGs had a 
Croatian author. 
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Figure 6. Mean gap between publication of a clinical practice guideline for diabetes and the 
references that it cited, for 15 European countries whose guidelines cited at least 75 references. 
Countries with > 600 cited references shown by blue bars; countries with > 250 cited references shown 
by striped bars; and countries with < 250 references shown by light blue bars. For country ISO codes, 
see Table 1. 
The final tally of cited references was 5,941 papers; this total included many duplicates as some 
papers were cited by several different CPGs (multiple citations)– the maximum being 17 cites for 
two papers. The “most-cited” five are listed in Table 7, which also shows the citing and cited 
countries. It is notable that although there are many citing countries to these five papers, the cited 
countries are primarily the UK (2.26 papers) and the US (1.96 papers) on a fractional count basis. 
The papers that were cited on the CPGs were, as expected, mainly in the field of diabetes 
research. Of the articles and reviews with a EUR31 address and published in the years 2002-13, 
1,121 of 1,569 (71%), were in the diabetes file. Table 6 shows that they were very well cited in 
the WoS compared with the average ACI for European papers in 2002-12 of 17.6 cites. 
Table 6. Comparison of five-year citation scores in the Web of Science for diabetes papers 
cited on European Clinical Practice Guidelines with the numbers of cites on these 
guidelines. 
Cites on diabetes CPGs Five-year cites (ACI) on WoS N 
1 36 1274 
2 67 193 
3 100 58 
4 196 26 
5 256 8 
6 to 9 376 8 
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Table 6. Five diabetes papers with many citations (N) on European clinical practice guidelines 
published in 2002-13, with identification of the citing and cited countries. For country codes, see 
Table 1. Numbers in parentheses under “Citing” are the numbers of CPGs from that country; under 
“Cited” they are the fractional counts. 
Reference N Citing Cited  
Holman-RR Paul-SK Bethel-MA Matthews-DR 
Neil-HAW (2008) 10-year follow-up of intensive 
glucose control in type 2 diabetes. New Engl J Med, 
Vol 359, Iss 15, pp 1577-1589 
17 AT, CZ, DE, ES (3), 
FI, HR, HU, IT, NL, 
PT (5), UK 
UK only 
Turner-RC and many others (1998) Intensive blood-
glucose control with sulphonylureas or insulin 
compared with conventional treatment and risk of 
complications in patients with type 2 diabetes 
(UKPDS 33). Lancet, Vol 352, Iss 9131, pp 837-
853 
17 AT (4), BE, CZ, ES 
(4), FI, HU, NL, PT, 
RO, SE, UK 
UK only 
Chitwood-M and many others (1993) The effect of 
intensive treatment of diabetes on the development 
and progression of long-term complications in 
insulin-dependent diabetes-mellitus. New Engl J 
Med, Vol 329, Iss 14, pp 977-986 
14 AT (4), BE, CZ, ES 
(4), FI (2), HU, RO, 
SE, UK 
US (0.92), 
CA (0.08) 
Patel-A and 24 others (2008) Intensive blood 
glucose control and vascular outcomes in patients 
with type 2 diabetes. New Engl J Med, Vol 358, Iss 
24, pp 2560-2572 
12 AT (2), ES (2), GR 
NL, PT (4), SE, UK 
UK (0.26), 
AU (0.22) 
and 8 others 
Knowler-WC Barrett-Connor-E Fowler-SE 
Hamman-RF Lachin-JM Walker-EA Nathan-DM 
(2008) Reduction in the incidence of type 2 diabetes 
with lifestyle intervention or metformin. New Engl 
J Med, Vol 346, Iss 6, pp 393-403 
11 AT (3), BE, DE, ES 
(2), FI (2), NL, UK 
US only 
European newspaper stories about diabetes research 
The file of newspaper stories about diabetes research contained 8,596 stories, of which 822 
entries (9.6%) concerned diabetes. This shows a substantial interest by the press in the disease, as 
diabetes research accounted for only 5.9% of European biomedical research and only 4.3% of the 
disease burden measured in Disability-Adjusted Life Years (DALYs), (Begum et al. 2017). The 
stories appeared in 30 different European newspapers from 22 countries, led by Daily Mail (UK) 
with 126, Le Soir (Belgium) with 111 and The Guardian (UK) with 102. The individual journals 
whose papers particularly attracted the journalists’ attention were high-profile general medical 
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journals, many of them weeklies such as The Lancet (61 papers), JAMA (47) and the New 
England Journal of Medicine (45). There were 125 stories that cited papers in diabetes journals 
(15%): this is far fewer than the number expected from their presence in diabetes research (42%, 
v.s.). The stories were categorised by our researchers, both on the application (disease area) and 
the type of research (e.g., drugs, genetics). Half of the stories concerned type 2 diabetes; less 
attention was given to type 1 (15%) and very little to the various sequelae, such as vascular 
effects (1.3%) and the effects on kidneys (1.3%) or eyes (1.1%). The stories concentrated on the 
causes of diabetes and how it could be prevented, rather than on methods of treatment. Thus, 22% 
were about the effects of diet, 19% about epidemiology, 17% about genetics and 15% about the 
effects of lifestyle choices. Only 10% covered treatment, mainly with drugs, and 8% discussed 
the provision of insulin. 
Some 150 of the stories (16%) quoted the views of commentators on the significance of the 
results; 50 were in the Daily Mail (UK), 30 in The Guardian (UK) and 14 each in Le Soir 
(Belgium) and Svenska Dagbladet (Sweden). There were 130 different individuals mentioned, led 
by Iain Frame (15 quotes) of Diabetes UK, a collecting charity. Diabetes UK was quoted in 38 
stories in total. The other main source of comments was universities, which were quoted 31 
times. 
As with the papers cited by CPGs, most European countries’ research was relatively over-cited in 
the newspaper stories, see Figure 7, which can be compared with Figure 3. There is a similarity 
between the two charts, but the over-citation ratios for most European countries are higher for the 
newspaper stories, particularly those for the top four, Finland (FI), Norway (NO), the UK and 
Belgium (BE). Once again, Asian research is largely neglected other than that from Singapore 
(SG). 
Figure 7. Over- (or under-) citation ratio for countries’ papers in European newspaper stories other 
than from own country (limited to those with at least 15 papers cited in the stories). European 
countries blue, north American countries red; south American country green; east Asian countries 
yellow; Australia orange. For country ISO codes, see Table 1. 
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A comparison of the over-citation ratios for own country and for papers cited by news stories 
from other countries is shown in Figure 8. 
Figure 8. OCR for 10 European countries’ papers cited in newspaper stories from own country 
(blue striped columns) and from stories from other European countries (red columns) compared 
with their presence in diabetes research, 2002-13, fractional counts. For country ISO codes, see Table 
1. 
Whereas the papers cited by CPGs were much more clinical than most diabetes research papers, 
the ones cited in news stories were more mixed. The mean RL of the papers was 1.58 and of the 
journals in which they were published, 2.01. These averages are rather comparable to the values 
for European diabetes research (1.68 and 1.91, respectively, v.s.). So, the newspapers included 
some quite basic research among the papers that they cited, because their primary concern was 
prevention rather than treatment. 
There were some papers that were cited in several different newspapers, though many fewer than 
with CPGs as we only covered 30 newspapers compared with 103 guidelines. The six top-cited 
papers are shown in Table 8. None of them are also in Table 7. The distribution of numbers of 
papers and counts of citations in newspaper stories is shown in Figure 9 which also shows the 
relationship for citations on CPGs. A power-law describes the relationship with high accuracy for 
both sets of cited papers. 
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Figure 9. Relationship between numbers of papers cited by diabetes CPGs (blue) and newspaper 
stories (red) and the numbers of citations by these documents.  
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Table 7. Diabetes papers cited in five or more European newspaper stories, 2002-13. For country 
codes, see Table 1. Numbers in parentheses under “Citing” are the numbers of CPGs from that 
country; under “Cited” they are the fractional counts. 
Reference N Citing Cited 
Sladek-R et al. A genome-wide association study 
identifies novel risk loci for type 2 diabetes. Nature, 
2007, Vol 445, Iss 7130, pp 881-885 
7 BE (2), FR, NL, 
PT, UK (3) 
CA (0.63), 
FR (0.21), 
UK (0.16) 
Nissen-SE et al. Effect of rosiglitazone on the risk of 
myocardial infarction and death from cardiovascular 
causes. New England Journal of Medicine, 2007, Vol 
356, Iss 24, pp 2457-2471 
6 DE, DK, FI, NL, 
UK (2) 
US only 
Burton-PR et al. Genome-wide association study of 
14,000 cases of seven common diseases and 3,000 
shared controls. Nature, 2007, Vol 447, Iss 7145, pp 
661-678 
5 ES, FR, RO, UK 
(2) 
AU (0.02), 
FR (0.02), 
GM (0.02), 
UK (0.94) 
Huxley-R et al. Coffee, Decaffeinated Coffee, and Tea 
Consumption in Relation to Incident Type 2 Diabetes 
Mellitus A Systematic Review With Meta-analysis. 
Archives of Internal Medicine, 2009, Vol 169, Iss 22, 
pp 2053-2063 
5 CZ, GR, NL (2), 
PL 
AU (0.2), 
FR (0.2), NL 
(0.2), UK 
(0.2), US 
(0.2) 
Micha-R et al. Red and Processed Meat Consumption 
and Risk of Incident Coronary Heart Disease, Stroke, 
and Diabetes Mellitus A Systematic Review and Meta-
Analysis. Circulation, 2010, Vol 121, Iss 21, pp 2271-
U52 
5 BE (2), DK, HR, 
UK 
US only 
Tasali-E et al. Slow-wave sleep and the risk of type 2 
diabetes in humans. Proceedings of the National 
Academy of Sciences of the United States of America, 
2008, Vol 105, Iss 3, pp 1044-1049 
5 BE, DE, UK (3) US only 
Obesity was the single most studied subject, with 110 papers (11%) including this word (together 
with obese and overweight) in their titles. Next came coffee with 34, exercise/physical activity 
with 25, and sleep with 24. All are concerned with prevention. 
We have generated seven different criteria for the relative evaluation of European countries’ 
research in diabetes, and Table 9 shows that no country dominates, although some are clearly 
scoring more highly than others. Four countries have a position in five of the seven orders of 
merit: Denmark (DK), Finland (FI), Switzerland (CH) and the UK, and Sweden (SE) is in four of 
them. This diversity of rankings suggests that it would be misleading to use just a single indicator 
of merit, and that different countries show to advantage on different measures (Martin, 1996). 
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Table 8. Ranking order of the European countries in diabetes research, 2002-13, on seven different 
criteria: Arith=arithmetic citation mean, Geom=geometric citation mean, 5%=presence in top cited 
5% of papers, OCR=over-citation ratio for own papers, compared with that for WS citations; 
Revs=percentage of reviews, CPGs=over-citation ratio for CPGs from other countries, NSs=over-
citation ratio for newspaper stories from other countries. For country ISO codes, see Table 1. 
  Citations in the serial literature Reviews CPGs NSs 
Rank Arith Geom 5% OCR % OCR OCR 
1 IS FI FI FR UK UK UK 
2 FI DK CH DK GR DK SE 
3 DK NL BE CH BG FI FI 
4 BE CH IS NL PT SE BE 
5 CH NO UK SE FR NL FR 
6 UK SE DK DE CH IT ES 
Although the last two columns record the practical effects of the diabetes research from different 
countries, there is some bias because we were unable to examine the CPGs and newspapers from 
all European countries, and the rankings to some extent reflect the national origins of these two 
types of document. For example, the newspaper stories were dominated by results from two UK 
newspapers (Daily Mail and The Guardian) which contained far more medical stories than most 
continental European newspapers. However, this dominance would not have affected the high 
ranking of the UK in other newspapers except that some papers took a few of their stories from 
those originally published in British newspapers. 
Discussion 
The number of CPGs available to diabetes practitioners has increased over the years. Papers cited 
in the guidelines tend to be more clinical in nature than the average for the journals in which they 
were published. This suggests a greater coherence and a focus on agreed models of care. 
Guidelines seem to be up-to-date, referencing relatively recent publications (the inter-quartile 
range of publication dates was between 2000 and 2008). However, there is heterogeneity across 
countries in terms of the delay in the uptake of most recent evidence in the guidelines, with some 
countries citing references a decade old on average. This could suggest the need to revise the 
updating process of some of the guidelines in order to facilitate incorporation of the most recent 
findings in the literature in the guidance for clinical practice. Additionally, the OCR (Figure 4) 
may reflect an information bias with respect to the citation of diabetes research from own country 
within the CPGs. This is particularly important in an era of evidence-based practices and such 
evaluation of the research evidence origin may in fact indicate factors related to the management 
of the disease in a particular country or healthcare system like Sweden or the other Scandinavian 
countries (Figure 3). However, the extent of this influence in clinical practice can perhaps be 
investigated further in a future study. Future evaluation of available CPGs for diabetes according 
to criteria of pragmatism and conciseness (Jackson and Feder 1998) should be conducted.  
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The analysis of dissemination trends for research results through newspaper stories is particularly 
relevant to define effective strategies to raise awareness of diabetes among the general public and 
promote evidence-based discourse. The presence of external commentators will help to give 
confidence and credibility in the advice being given, particularly if they are from well-respected 
sources such as academia and collecting charities. The majority of stories concerned type 2 
diabetes, with less attention given to other types of diabetes and the effects of the disease. Most 
stories concentrated on causes and prevention, rather than treatment. While this analysis offers a 
general overview of subject areas and the focus of newspaper stories, further studies could build 
on existing literature on diabetes in the news media (Gollust and Lantz 2009; Hellyer and 
Haddock-Fraser 2010; Rock 2005) to conduct a detailed content analysis of the stories found. 
Some limitations have to be taken into consideration in the interpretation of the study results. 
First, evidence suggests that health-related articles in social sciences in languages other than 
English tend to be under-recorded (Nederhof 2006), and under-represented in the bibliographic 
databases (Van Leeuwen et al. 2001). A certain degree of publication bias related to language 
should therefore be taken into account. Second, the research articles found were not individually 
evaluated for quality. This is a general limitation of bibliometric research (Similowski and 
Derenne 1994). Moreover, differences in national contexts limit the value of a one-size-fits-all 
bibliometric method for research evaluation: methods tailored to different contexts may provide 
more reliable results (Haustein and Larivière 2015). 
Nevertheless, the results provide a novel insight into the evaluation of European countries’ 
performance and the impact of different subject areas of diabetes research, both through the 
dissemination of study findings in the academic serial literature, and through their use in clinical 
practice and information to the general public through the mass media. 
Conclusions 
This paper was intended to show three different sources of indicators using citation data, namely 
the serial literature as recorded in the WoS, references on clinical practice guidelines, and stories 
in newspapers. Each can provide valid measures of the impact and utility of medical research 
publications, and countries may perform differently on the individual indicators. So, there were 
three different measures of citation performance for the EUR31 countries, and their rankings 
differed. None of them can be regarded as the most important: multiple indicators are just better 
than one (Martin, 1996). The comparisons are between countries, and to lesser extent subject 
areas, within diabetes. The increased emphasis nowadays being placed on demonstration of the 
social and economic impacts (Di Cagno, Fabrizi & Meliciani, 2014; Habets, van Delden & 
Bredenoord, 2014; Chowdhury, Koya & Philipson, 2016; Prettner & Werner, 2016; Solarin & 
Yen, 2016) stemming from research make the described methodologies herein of particular value 
to future evaluations of medical research. 
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